These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32695574)

  • 1. Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome.
    Tcvetkov N; Gusak A; Morozova E; Moiseev I; Baykov V; Barabanshikova M; Lepik K; Bakin E; Vlasova J; Osipova A; Zubarovskaya L; Afanasyev B
    Leuk Res Rep; 2020; 14():100215. PubMed ID: 32695574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Landscape of alterations in the checkpoint system in myelodysplastic syndrome and implications for prognosis.
    Moiseev I; Tcvetkov N; Epifanovskaya O; Babenko E; Parfenenkova A; Bakin E; Yurovskaya K; Morozova E
    PLoS One; 2022; 17(10):e0275399. PubMed ID: 36282797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints.
    Hidalgo-López JE; Kanagal-Shamanna R; Quesada AE; Thakral B; Hu Z; Mitsuhashi T; Yabe M; Garcia-Manero G; Bueso-Ramos CE
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S16-S25. PubMed ID: 28760297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
    Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and Prognostic Implications of Caspase-1 and PD-L1 Co-Expression Patterns in Myelodysplastic Syndromes.
    Graf JR; Forster S; Bruehl FK; Banz Y; Hallal M; Brodard J; Bacher VU; Allam R; Schürch CM; Bonadies N
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter?
    Bailly C; Thuru X; Quesnel B
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.
    Dama P; Tang M; Fulton N; Kline J; Liu H
    J Immunother Cancer; 2019 Jul; 7(1):175. PubMed ID: 31291985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes.
    Asayama T; Tamura H; Ishibashi M; Kuribayashi-Hamada Y; Onodera-Kondo A; Okuyama N; Yamada A; Shimizu M; Moriya K; Takahashi H; Inokuchi K
    Oncotarget; 2017 Oct; 8(51):88904-88917. PubMed ID: 29179486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC.
    Mahmoudian RA; Mozhgani S; Abbaszadegan MR; Mokhlessi L; Montazer M; Gholamin M
    J Mol Histol; 2021 Jun; 52(3):597-609. PubMed ID: 33884540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
    Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
    Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma.
    Takeuchi M; Miyoshi H; Nakashima K; Kawamoto K; Yamada K; Yanagida E; Muta H; Moritsubo M; Umeno T; Suzuki T; Seto M; Ohshima K
    Ann Hematol; 2020 May; 99(5):1093-1098. PubMed ID: 32157421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.
    Feucht J; Kayser S; Gorodezki D; Hamieh M; Döring M; Blaeschke F; Schlegel P; Bösmüller H; Quintanilla-Fend L; Ebinger M; Lang P; Handgretinger R; Feuchtinger T
    Oncotarget; 2016 Nov; 7(47):76902-76919. PubMed ID: 27708227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia.
    Yang X; Ma L; Zhang X; Huang L; Wei J
    Exp Hematol Oncol; 2022 Mar; 11(1):11. PubMed ID: 35236415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging role of immune checkpoint based approaches in AML and MDS.
    Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
    Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression patterns of immune checkpoints in acute myeloid leukemia.
    Chen C; Liang C; Wang S; Chio CL; Zhang Y; Zeng C; Chen S; Wang C; Li Y
    J Hematol Oncol; 2020 Apr; 13(1):28. PubMed ID: 32245463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma.
    Jing W; Gershan JA; Weber J; Tlomak D; McOlash L; Sabatos-Peyton C; Johnson BD
    J Immunother Cancer; 2015; 3(1):2. PubMed ID: 25614821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.
    Park SH; You E; Park CJ; Cho YU; Jang S; Im HJ; Seo JJ; Park HS; Lee JH
    Cytometry B Clin Cytom; 2020 Jul; 98(4):336-347. PubMed ID: 32268011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
    Shrestha R; Prithviraj P; Anaka M; Bridle KR; Crawford DHG; Dhungel B; Steel JC; Jayachandran A
    Front Oncol; 2018; 8():269. PubMed ID: 30057891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.